Understanding how platelet strength relates to bleeding risk in immune thrombocytopenia
Official title: Leveraging platelet contraction cytometry for immune thrombocytopenia
Funded at Emory University · NIH-11042700 · Data updated 2026-11-12
This study is looking at how strong individual platelets are in people with immune thrombocytopenic purpura (ITP) to see if that can help doctors figure out who might be at a higher risk for bleeding and need treatment, so they can avoid giving unnecessary treatment to those who are less at risk.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Emory University NIH-funded |
| Lab location | 1 site (Atlanta, United States) |
| Project start | January 15, 2021 |
| Project end | December 31, 2025 |
| Funding year | 2025 |
| Award (this year) | $384,010 |
| NIH project number | 5R01HL155330-05 |
| Project ID | NIH-11042700 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research include children and adults diagnosed with immune thrombocytopenic purpura (ITP).
✕Less likely to help
Patients with other bleeding disorders or those without a diagnosis of immune thrombocytopenic purpura may not benefit from this research.
What this research studies
This research investigates the relationship between the contractile force of individual platelets and the risk of bleeding in patients with immune thrombocytopenic purpura (ITP). By utilizing a high-throughput platelet contraction cytometer, the study aims to measure the strength of platelets in both children and adults diagnosed with ITP. The goal is to identify a potential biomarker that could help clinicians determine which patients are at higher risk for bleeding and may require treatment, thereby avoiding unnecessary side effects for those at lower risk.
Why it matters
Potential benefit: If successful, this research could lead to improved risk assessment and treatment strategies for patients with immune thrombocytopenia, ultimately reducing the incidence of serious bleeding events.
How similar studies have gone: While the approach of using platelet contractile force as a biomarker is novel, preliminary results suggest a strong correlation with bleeding risk, indicating potential for success.
Where this research is happening
-
Emory University
Atlanta, United States Active
Researchers
- Principal investigator: Myers, David Richard — Emory University
- Study coordinator: Myers, David Richard
Related research
Other NIH-funded projects on the same topics.
-
Molecular mechanisms behind immune-related low platelets and clots in transfusion medicine
This grant supports a team of researchers to understand how immune factors cause low platelets and abnormal clots, with a focus on transfusion medicine and pediatric to adult patients.
-
Understanding Immune Blood Disorders Affecting Platelets
This program explores how the immune system causes low platelet counts and blood clots in people of all ages, from newborns to adults.
-
Developing a new treatment for immune thrombocytopenia using a specialized enzyme
This study is testing a new treatment for people with immune thrombocytopenia (ITP) that uses a specially designed enzyme to help reduce harmful antibodies and improve platelet counts, aiming to provide a safer and more effective option than what’s currently available.
-
Understanding how immune responses affect blood platelet levels
This study is looking into how the immune system affects low platelet counts and blood clotting issues, with the goal of finding better treatments for people of all ages, from newborns to adults.
-
New ideas to understand, diagnose, and treat heparin-induced thrombocytopenia
A Mayo Clinic led study will look at the different kinds of HIT antibodies to improve diagnosis and treatment for people with HIT.
-
Second-generation BLVRB inhibitors to help chemotherapy patients with low platelets
A new drug candidate is being developed to raise platelet counts in patients whose cancer treatment lowers them, reducing bleeding risk.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.